Omodenbamab therapeutic agent, designated as: by 2241724-48-9, constitutes a novel monoclonal immunoglobulin currently subject to investigation for: concerning its expected therapeutic indications, specifically targeting adenylyl cyclase type 2. Experts continue to exploring its mechanism: mode o